Skip to main content

BRIEF RESEARCH REPORT article

Front. Nephrol.
Sec. Glomerular disease
Volume 4 - 2024 | doi: 10.3389/fneph.2024.1471078

Increased levels of antibodies to synaptopodin and annexin 1 in patients with primary podocytopathies

Provisionally accepted
Natalia Chebotareva Natalia Chebotareva 1*Evgeniya Kharionovskaya Evgeniya Kharionovskaya 1Evgenia Birukova Evgenia Birukova 1Anatoliy Vinogradov Anatoliy Vinogradov 2Natalia Sergeeva Natalia Sergeeva 3Igor Alentov Igor Alentov 3Alexey Kononikhin Alexey Kononikhin 4Evgeny Nikolaev Evgeny Nikolaev 4Sergey Moiseev Sergey Moiseev 1
  • 1 I.M. Sechenov First Moscow State Medical University, Moscow, Russia
  • 2 Lomonosov Moscow State University, Moscow, Moscow, Russia
  • 3 P.Herzen Moscow Oncology Research Institute (MORI), Moscow, Moscow Oblast, Russia
  • 4 Skolkovo Institute of Science and Technology, Moscow, Moscow Oblast, Russia

The final, formatted version of the article will be published soon.

    Circulating anti-podocyte antibodies have been proposed as potential factors contributing to increased permeability in primary podocytopathies, such as Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS). The aim of the study was to to assess the levels of antibodies targeting synaptopodin and annexin 1 in the blood serum of patients diagnosed with nephrotic syndrome, with the aim of evaluating their potential utility in diagnosing primary podocytopathies. Methods: The study included a total of 72 patients diagnosed with nephrotic syndrome, alongside 21 healthy subjects for comparison. Among the patients, 38 were diagnosed with FSGS, 12 with MCD, and 22 with MN. The levels of anti-synaptopodin and anti-annexin-1 antibodies were quantified using ELISA.Results: The levels of antibodies to annexin 1 and anti-synaptopodin in the blood were found to be higher in patients diagnosed with MCD and FSGS compared to those with MN and healthy individuals. A model incorporating both antibodies demonstrated higher sensitivity (80.9%) and specificity (81.3%) with an AUC of 0.859 (95% CI 0.760-0.957). Notably, serum levels of annexin 1 and anti-synaptopodin antibodies did not predict the response to prednisolone and/or CNI therapy.Discussion. Levels of antibodies targeting synaptopodin and annexin 1 were notably elevated in patients diagnosed with MCD and FSGS compared to those with MN and healthy controls. A panel comprising both antibodies demonstrated moderate to high sensitivity and specificity for diagnosis MCD or FSGS.

    Keywords: minimal change disease, focal segmental glomerulosclerosis, Podocytopathy, Annexin 1, Synaptopodin

    Received: 26 Jul 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Chebotareva, Kharionovskaya, Birukova, Vinogradov, Sergeeva, Alentov, Kononikhin, Nikolaev and Moiseev. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Natalia Chebotareva, I.M. Sechenov First Moscow State Medical University, Moscow, Russia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.